dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tablets

Phase 1Recruiting

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Conditions

High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Trial Timeline

Oct 1, 2023 → Dec 1, 2028

NCT ID

NCT06099990

About dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tablets

dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tablets is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06099990. Target conditions include High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06099990	Phase 1	Recruiting	Oct 1, 2023	Dec 1, 2028	High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)